Identification of Molecular Factors Associated with Response to Interleukin-2

与 IL-2 反应相关的分子因素的鉴定

• 批准号: 8553056
• 负责人: James C Yang
• 金额: $ 13.88万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8553056
• 关键词: Biological Assay; Clinical; Collaborations; Dose; IL2 gene; Immune; Interleukin-2; Molecular; Outcome; Patients; Peripheral Blood Mononuclear Cell; Proteins; Proteomics; Renal carcinoma; Sampling; Serum; Techniques; Testing; Unresectable; Validation; Work; melanoma; response; tumor

To this point, over 90 patients (most with melanoma and including a dozen with objective clinical responses) have had serum and peripheral blood mononuclear cells (PBMC) collected during their initial therapy with IL-2. Over 30 immune related proteins have been interrogated in pretreatment sera by multiplex assay. The pre-treatment PBMC and the PBMC rebound occuring after stopping IL2 have been subjected to Affymetics array analysis in a test set and we are accumulating a validation set of samples. We have also entered into a collaboration with MD Anderson CC to exchange anonymous samples from patients treated with high dose IL2 to use as part of the validation set.Finding molecular factors associated with one of the only curative therapies for melanoma and renal cancer would not only allow treatment to focus on those most likely to benefit, but it could also provide clues to the mechanism by which IL-2 is working.

到目前为止，超过90名患者（大多数患有黑色素瘤，包括十几个具有客观临床反应）的患者有血清和外周血单核细胞（PBMC）在初次使用IL-2治疗期间收集的。 通过多重测定，已在预处理血清中询问了30多种免疫相关蛋白。 停止IL2后发生的预处理PBMC和PBMC反弹已在测试集中经过伴侣阵列分析，我们正在积累一个样本验证集。 我们还与MD Anderson CC进行了合作，以交换来自高剂量IL2治疗的患者的匿名样本，以用作验证集的一部分。与黑色素瘤和肾脏癌的唯一治疗疗法相关的分子因素和肾脏癌的唯一治疗疗法相关，不仅可以将重点放在最可能的好处，而且还可以通过机构来提供电路，以便通过机械进行机械效果。